Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pharmacy retailing (nz) ltd t/a healthcare logistics - benzoyl peroxide 10%{relative};   - topical gel - 10% w/w - active: benzoyl peroxide 10%{relative}   excipient: acrylates copolymer carbomer 940 colloidal silicon dioxide disodium edetate dihydrate docusate sodium glycerol poloxamer propylene glycol sodium hydroxide water - latest regulatory activity

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

bausch & lomb (nz) ltd - phenylephrine hydrochloride 10%;  ;   - eye drops, solution - 10 % - active: phenylephrine hydrochloride 10%     excipient: disodium edetate dihydrate sodium metabisulfite water for injection

Marekani - Kiingereza - NLM (National Library of Medicine)

par pharmaceutical inc. - balsalazide disodium (unii: 1xl6bji034) (balsalazide - unii:p80al8j7zp) - balsalazide disodium 1.1 g

Marekani - Kiingereza - NLM (National Library of Medicine)

btg international inc - edetate calcium disodium anhydrous (unii: 8u5d034955) (calcium cation - unii:2m83c4r6zb) -

Marekani - Kiingereza - NLM (National Library of Medicine)

rising pharmaceuticals, inc. - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium injection should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

Marekani - Kiingereza - NLM (National Library of Medicine)

casper pharma llc - edetate calcium disodium (unii: 25ih6r4sgf) (edetic acid - unii:9g34hu7rv0) - edetate calcium disodium injection is indicated for the reduction of blood levels and depot stores of lead in lead poisoning (acute and chronic) and lead encephalopathy, in both pediatric populations and adults. chelation therapy should not replace effective measures to eliminate or reduce further exposure to lead. edetate calcium disodium injection should not be given during periods of anuria, nor to patients with active renal disease or hepatitis.

Australia - Kiingereza - APVMA (Australian Pesticides and Veterinary Medicines Authority)

dermcare-vet pty. ltd. - disodium edetate; poly(hexamethylene) biguanidine hydrochloride - misc. aural, ophthalmic, oro/naso pharyngeal - disodium edetate ungrouped active 1.2 g/l; poly(hexamethylene) biguanidine hydrochloride active 2.0 g/l - ear,nose,throat preps. - dog | bitch | castrate | puppy - ear wax removal | otitis externa | acute canine otitis | associated with yeast &/or bac | chronic canine otitis | ear cleaner | malassezia pachydermatis | otitis (canine)

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

pacific pharmaceuticals limited (part of mylan) - benzoyl peroxide 10%{relative} (as hydrous) - topical gel - 10 % - active: benzoyl peroxide 10%{relative} (as hydrous) excipient: carbomer 940 colloidal silicon dioxide disodium edetate dihydrate docusate sodium poloxamer propylene glycol purified water

Nyuzilandi - Kiingereza - Medsafe (Medicines Safety Authority)

merck sharp & dohme (new zealand) limited - interferon alfa-2b 10 miu/ml;   - solution for injection - 10 miu/ml - active: interferon alfa-2b 10 miu/ml   excipient: dibasic sodium phosphate disodium edetate dihydrate metacresol monobasic sodium phosphate monohydrate polysorbate 80 sodium chloride water for injection

Marekani - Kiingereza - NLM (National Library of Medicine)

acella pharmaceuticals, llc - sulfacetamide sodium (unii: 4nrt660kjq) (sulfacetamide - unii:4965g3j0f5), sulfur (unii: 70fd1kfu70) (sulfur - unii:70fd1kfu70) - sulfacetamide sodium 10 mg in 1 g - indications: sodium sulfacetamide 10% - sulfur 5% cleanser is indicated in the topical control of acne vulgaris, acne rosacea and seborrheic dermatitis. contraindications: sodium sulfacetamide 10% - sulfur 5% cleanser is contraindicated for use by patients having known hypersensitivity to sulfonamides, sulfur or any other component of this preparation. sodium sulfacetamide 10% - sulfur 5% cleanser is not to be used by patients with kidney disease. pediatric use: safety and effectiveness in children under the age of 12 have not been established.